Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP & Chief Legal Officer | September 13, 2011 | September 14, 2011 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date September 13, 2011 · Filed September 14, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,999 |
Ending reported balance
After 2011-09-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2011-09-13 · Exercise / conversion · Acquired 22,000 · Balance 134,999 Row 2 · 2011-09-13 · Sale · Disposed 22,000 · Balance 112,999 F1: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $18.75 · Expires 2011-09-23 | Direct | 0 |
Reported balance
After 2011-09-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2011-09-13 · Exercise / conversion · Disposed 22,000 · Balance 0 F3: Fully vested. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 5,021 |
Reported balance
Holding disclosure · report date 2011-09-13 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,021 |
| Common StockSEC Table I · non-derivative | IndirectTrustee of Trusts | 174,167 |
Reported balance
Holding disclosure · report date 2011-09-13 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 174,167 F2: Kenneth S. Boger is the trustee for trusts established for the benefit of the three adult children of Joshua S. Boger (a director of the issuer). |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1.
F2: Kenneth S. Boger is the trustee for trusts established for the benefit of the three adult children of Joshua S. Boger (a director of the issuer).
F3: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2009 Filed Jul 29, 2009 18:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 4,173 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0000875320-09-000071 · edgar.xml · derivative · entry 7 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,024 Underlying: Common Stock · 4,173 shares Expires 2015-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| July 28, 2009 Filed Jul 29, 2009 18:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 14,179 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0000875320-09-000071 · edgar.xml · derivative · entry 6 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,820 Underlying: Common Stock · 14,179 shares Expires 2011-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| July 28, 2009 Filed Jul 29, 2009 18:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 19,898 | $36.00 | $716,328.00 |
DisclosureSEC source: 0000875320-09-000071 · edgar.xml · nonDerivative · entry 4 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,857 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan established under Rule 10b5-1. Read SEC document |
| July 28, 2009 Filed Jul 29, 2009 18:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,547 | $10.41 | $16,104.27 |
DisclosureSEC source: 0000875320-09-000071 · edgar.xml · nonDerivative · entry 3 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2009 Filed Jul 29, 2009 18:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,173 | $17.16 | $71,608.68 |
DisclosureSEC source: 0000875320-09-000071 · edgar.xml · nonDerivative · entry 2 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2009 Filed Jul 29, 2009 18:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 14,178 | $18.75 | $265,837.50 |
DisclosureSEC source: 0000875320-09-000071 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2009 Filed Jul 20, 2009 19:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,500 | $0.00 Strike: $33.28 | $0.00 |
DisclosureSEC source: 0000875320-09-000063 · edgar.xml · derivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common stock · 30,500 shares Expires 2019-07-15 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/16/09. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 11,203 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · derivative · entry 18 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,547 Underlying: Common Stock · 11,203 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 10,803 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · derivative · entry 17 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,197 Underlying: Common Stock · 10,803 shares Expires 2015-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 4 years. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 18,000 | $0.00 Strike: $11.27 | $0.00 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · derivative · entry 16 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2014-10-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 2,700 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · derivative · entry 15 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,700 shares Expires 2013-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 29,998 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · derivative · entry 14 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,998 shares Expires 2013-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 3,160 | $0.00 Strike: $15.60 | $0.00 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · derivative · entry 13 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,160 shares Expires 2013-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 4,821 | $0.00 Strike: $15.87 | $0.00 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · derivative · entry 12 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,821 shares Expires 2012-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 27,316 | $0.00 Strike: $15.87 | $0.00 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · derivative · entry 11 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,316 shares Expires 2012-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 108,001 | $36.00 | $3,888,036.00 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · nonDerivative · entry 9 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,857 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan established under Rule 10b5-1. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 11,203 | $10.41 | $116,623.23 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · nonDerivative · entry 8 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 10,803 | $17.16 | $185,379.48 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · nonDerivative · entry 7 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 18,000 | $11.27 | $202,860.00 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · nonDerivative · entry 6 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,700 | $9.07 | $24,489.00 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · nonDerivative · entry 5 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 29,998 | $15.60 | $467,968.80 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · nonDerivative · entry 4 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,160 | $15.60 | $49,296.00 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · nonDerivative · entry 3 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,821 | $15.87 | $76,509.27 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · nonDerivative · entry 2 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2009 Filed Jun 30, 2009 20:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 27,316 | $15.87 | $433,504.92 |
DisclosureSEC source: 0000875320-09-000051 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2009 Filed May 11, 2009 18:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11,826 | $28.89 | $341,653.14 |
DisclosureSEC source: 0000875320-09-000025 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,857 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan established under Rule 10b5-1. F2 · price: Open market sales repoted on this line occurred at a weighted average price of $28.89 (range $28.70 to $29.20). F3 · price: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 45,750 | $0.00 Strike: $33.55 | $0.00 |
DisclosureSEC source: 0000875320-09-000004 · edgar.xml · derivative · entry 4 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2019-02-04 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/09. Read SEC document |
| February 05, 2009 Filed Feb 6, 2009 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-09-000004 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,683 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/5/2013, subject to 50% acceleration upon filing a new drug application with the FDA for telaprevir and 50% acceleration upon the approval of a new drug application for telaprevir. Read SEC document |
| November 18, 2008 Filed Nov 19, 2008 17:31 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 15,000 | $26.69 | $400,350.00 |
DisclosureSEC source: 0000875320-08-000085 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,517 F1 · price: Open market sales reported on this line occurred at a wieghted average price of $26.69 (range $26.60 to $26.82). F2 · price: Mr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 24, 2008 Filed Jul 25, 2008 14:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Options · Derivative | 30,500 | $0.00 Strike: $32.16 | $0.00 |
DisclosureSEC source: 0000875320-08-000053 · edgar.xml · derivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2018-07-23 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/24/2008. Read SEC document |
| February 07, 2008 Filed Feb 11, 2008 20:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,500 | $0.00 Strike: $18.93 | $0.00 |
DisclosureSEC source: 0000875320-08-000004 · edgar.xml · derivative · entry 4 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2018-02-06 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/07/2008, subject to shareholder approval. Read SEC document |
| February 07, 2008 Filed Feb 11, 2008 20:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 8,133 | $0.01 | $81.33 |
DisclosureSEC source: 0000875320-08-000004 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,160 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 2/7/2012, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| July 12, 2007 Filed Jul 16, 2007 17:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,500 | $0.00 Strike: $28.84 | $0.00 |
DisclosureSEC source: 0000875320-07-000074 · edgar.xml · derivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2017-07-11 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/12/2007. Read SEC document |
| May 07, 2007 Filed May 8, 2007 18:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12,684 | $30.60 | $388,130.40 |
DisclosureSEC source: 0000875320-07-000045 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,677 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan established under rule 10b5-1. Read SEC document |
| April 30, 2007 Filed May 1, 2007 15:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 12,000 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-07-000041 · edgar.xml · derivative · entry 5 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,750 Underlying: Common Stock · 12,000 shares Expires 2015-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 4 years from 2/3/2005. Read SEC document |
| April 30, 2007 Filed May 1, 2007 15:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12,000 | $31.35 | $376,200.00 |
DisclosureSEC source: 0000875320-07-000041 · edgar.xml · nonDerivative · entry 2 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,361 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan established under rule 10b5-1. Read SEC document |
| April 30, 2007 Filed May 1, 2007 15:58 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 12,000 | $10.41 | $124,920.00 |
DisclosureSEC source: 0000875320-07-000041 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2007 Filed Apr 2, 2007 20:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Options · Derivative | 11,700 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0000875320-07-000032 · edgar.xml · derivative · entry 5 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,700 Underlying: Common Stock · 11,700 shares Expires 2013-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 4 years from 12/11/2003. Read SEC document |
| March 30, 2007 Filed Apr 2, 2007 20:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 11,700 | $28.08 | $328,536.00 |
DisclosureSEC source: 0000875320-07-000032 · edgar.xml · nonDerivative · entry 2 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,361 F1 · kind: Transaction made pursuant to Mr. Boger's company approved trading plan established under rule 10b5-1. Read SEC document |
| March 30, 2007 Filed Apr 2, 2007 20:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 11,700 | $9.07 | $106,119.00 |
DisclosureSEC source: 0000875320-07-000032 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2007 Filed Jan 26, 2007 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 45,750 | $0.00 Strike: $36.30 | $0.00 |
DisclosureSEC source: 0000875320-07-000011 · edgar.xml · derivative · entry 4 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,750 Underlying: Common Stock · 45,750 shares Expires 2017-01-23 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 01/24/2007. Read SEC document |
| January 24, 2007 Filed Jan 26, 2007 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,166 | $0.01 | $101.66 |
DisclosureSEC source: 0000875320-07-000011 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,361 F1 · shares: Stock grant made under 2006 Stock and Option Plan, vesting on 1/24/2011, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| July 20, 2006 Filed Jul 24, 2006 17:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 30,500 | $0.00 Strike: $35.35 | $0.00 |
DisclosureSEC source: 0000875320-06-000062 · edgar.xml · derivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,445 Underlying: Common Stock · 30,500 shares Expires 2016-07-19 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/20/2006. Read SEC document |
| February 02, 2006 Filed Feb 6, 2006 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 73,500 | $0.00 Strike: $35.64 | $0.00 |
DisclosureSEC source: 0000875320-06-000011 · edgar.xml · derivative · entry 4 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,945 Underlying: Common Stock · 73,500 shares Expires 2016-02-01 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/02/2006. Read SEC document |
| February 02, 2006 Filed Feb 6, 2006 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 12,200 | $0.01 | $122.00 |
DisclosureSEC source: 0000875320-06-000011 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,529 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting on 2/2/2010, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| July 20, 2005 Filed Jul 22, 2005 19:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 18,000 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0000875320-05-000041 · edgar.xml · derivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,445 Underlying: Common Stock · 18,000 shares Expires 2015-07-19 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/20/2005. Read SEC document |
| February 03, 2005 Filed Feb 7, 2005 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 24,750 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0000875320-05-000006 · edgar.xml · derivative · entry 4 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,445 Underlying: Common Stock · 24,750 shares Expires 2015-02-02 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 02/03/2005. Read SEC document |
| February 03, 2005 Filed Feb 7, 2005 21:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,700 | $0.01 | $57.00 |
DisclosureSEC source: 0000875320-05-000006 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,620 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting on 2/3/2009, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| October 07, 2004 Filed Oct 12, 2004 18:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 18,000 | $0.00 Strike: $11.27 | $0.00 |
DisclosureSEC source: 0000875320-04-000104 · edgar.xml · derivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,695 Underlying: Common Stock · 18,000 shares Expires 2014-10-06 F1 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting quarterly over 4 years. Read SEC document |
| May 06, 2004 Filed May 10, 2004 19:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 65,000 | $0.01 | $650.00 |
DisclosureSEC source: 0000875320-04-000047 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,920 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting 50% on May 6, 2009, subject to acceleration upon achievement of a performance-based milestone based on Company profitability, and 50% on May 6, 2007. Read SEC document |
| December 11, 2003 Filed Dec 15, 2003 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 14,400 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0000875320-03-000054 · edgar.xml · derivative · entry 4 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,695 Underlying: Common Stock · 14,400 shares Expires 2013-12-10 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 12/11/2003. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.